Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Acute Myeloid Leukemia Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

109 recruiting trials for Acute Myeloid Leukemia. Eligibility criteria explained in plain English.

TrialFinderData lists 109 Acute Myeloid Leukemia clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 2 is the largest group at 39% (30 studies); the largest phase groups are Phase 2: 30, Phase 1: 24, Phase 1 / Phase 2: 12, Phase 3: 4.

Research is led by Institute of Hematology & Blood Diseases Hospital, China (6), National Cancer Institute (NCI) (4), UNC Lineberger Comprehensive Cancer Center (3), among the most active sponsors registered for these trials.

The most frequently studied intervention is Venetoclax (drug, 10 trials), followed by Cyclophosphamide, Biospecimen Collection.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
109
Total Trials
109
Recruiting Now
4
Phase 3 Trials
10
Sponsors

Track Acute Myeloid Leukemia trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 2NCT06447090

VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT

This clinical trial included 30 cases and aimed to understand the effectiveness and safety of the VMAC regimen combined with donor lymphocyte infusion (DLI) in the treatment of...

Sponsor: Institute of Hematology & Blood Diseases Hospital, ChinaEnrolling: 301 location
RECRUITINGNCT06860880

Combating Cancer-Related Fatigue: A Personalized Supportive Care Program

This health services study will assess a multidisciplinary intervention program directed at fatigue mitigation among patients diagnosed with indolent lymphomas. Specifically, 30...

Sponsor: UNC Lineberger Comprehensive Cancer CenterEnrolling: 401 location
RECRUITINGPhase 2NCT04793919

Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia

The trial is open to all patients with a diagnosis of acute promyelocytic leukemia (APL) who are PCR-positive for the PML-RARα transcript and less than 18 years of age.

Sponsor: Associazione Italiana Ematologia Oncologia PediatricaEnrolling: 8920 locations
RECRUITINGPhase 1NCT07347171

A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies

The goal of this clinical trial is to learn about the safety of drug CG009301. It also learns if drug CG009301 works to treat in Participants with relapsed or refractory adult...

Sponsor: Cullgen (Shanghai),IncEnrolling: 453 locations
RECRUITINGPhase 1 / Phase 2NCT05674175

Co-administration of CART22-65s and huCART19 for B-ALL

This study will evaluate the safety and efficacy of administering two CAR T cell products, huCART19 and CART22-65s, in children with advanced B cell Acute Lymphoblastic Leukemia...

Sponsor: Stephan Grupp MD PhDEnrolling: 931 location
RECRUITINGPhase 1 / Phase 2NCT06585345

Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell in Patients With Relapsed/Refractory Acute Leukemia

Acute leukemia is a malignant clonal disease of hematopoietic stem cells. At present, the treatment for acute leukemia is relatively limited, and it is still based on...

Sponsor: The General Hospital of Western Theater CommandEnrolling: 2001 location
RECRUITINGNCT07326930

Tracjectories and Predictors of Chemotherapy Induced Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia

The goal of this study is to explore the trajectory patterns of chemotherapy induced peripheral neuropathy over the course of chemotherapy and identify predictors of distinct...

Sponsor: The Hong Kong Polytechnic UniversityEnrolling: 1733 locations
RECRUITINGPhase 1NCT02074839

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies...

Sponsor: Institut de Recherches Internationales ServierEnrolling: 29120 locations
RECRUITINGPhase 2NCT06084819

Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

The purpose of this study is to compare the efficacy and safety of venetoclax combined with CACAG regimen with BAT regimen in the treatment of relapsed/refractory acute myeloid...

Sponsor: Chinese PLA General HospitalEnrolling: 2001 location
RECRUITINGPhase 2 / Phase 3NCT06607419

Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia

The goal of this clinical trial is to evaluate the efficacy of Blinatumomab in pediatric patient with newly diagnosed acute B-Lymphoblastic leukemia with poor response to early...

Sponsor: Shanghai Jiao Tong University School of MedicineEnrolling: 904 locations
RECRUITINGNCT06756022

Dolasetron for the Prevention of CINV in Children With Acute Lymphoblastic Leukemia

This is a prospective, multicenter, real-world study of 500 participants with childhood acute lymphoblastic leukemia who are scheduled to receive dolasetron mesylate injection for...

Sponsor: Anhui Provincial Children's HospitalEnrolling: 5001 location
RECRUITINGPhase 1NCT04375631

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of...

This phase I trial studies the best dose of total body irradiation when given with cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) or idarubicin, fludarabine,...

Sponsor: Fred Hutchinson Cancer CenterEnrolling: 1201 location
RECRUITINGPhase 2NCT06409936

PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML

A phase 2, interventional, randomized unblinded study will be conducted in newly diagnosed CP CML patients, to investigate the efficacy and the safety of asciminib at a dose of 80...

Sponsor: Gruppo Italiano Malattie EMatologiche dell'AdultoEnrolling: 16011 locations
RECRUITINGPhase 1NCT07295951

A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia

The purpose of this study is to assess how the body absorbs, breaks down (metabolism), and removes (excretes) radiolabeled bleximenib (a drug molecule that has been chemically...

Sponsor: Janssen Research & Development, LLCEnrolling: 101 location
RECRUITINGPhase 2NCT05672251

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

This phase II trial studies the safety and how well of loncastuximab tesirine when given together with mosunetuzumab works in treating patients with diffuse large B-cell lymphoma...

Sponsor: City of Hope Medical CenterEnrolling: 361 location
RECRUITINGPhase 2NCT07238712

Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies...

Optimization of bendamustine-containg graft-versus-host disease (GVHD) prophylaxis to reduce the incidence of secondary haemophagocytic lymphohistiocytosis and GVHD

Sponsor: St. Petersburg State Pavlov Medical UniversityEnrolling: 601 location
RECRUITINGPhase 2NCT04741945

Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDS

This is a single-arm pilot study of the feasibility and safety of metformin in patients with clonal cytopenia of undetermined significance (CCUS) or lower-risk myelodysplastic...

Sponsor: Kirsten GrønbækEnrolling: 401 location
RECRUITINGPhase 2NCT03136146

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic...

This phase II trial studies the side effects and how well combination chemotherapy works in treating patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, Burkitt...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 421 location
RECRUITINGNCT05588154

Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis...

Background: Myelodysplastic syndromes (MDS) are disorders of blood stem cells that can develop into blood cancers. Treatment options are limited. To find better treatments,...

Sponsor: National Cancer Institute (NCI)Enrolling: 10001 location
RECRUITINGPhase 1 / Phase 2NCT03934372

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to \< 18 years with advanced leukemias,...

Sponsor: Incyte Biosciences International SàrlEnrolling: 7020 locations
RECRUITINGPhase 2NCT07228273

Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid...

This phase II trial compares induction and consolidation therapy with fludarabine, cytarabine, idarubicin, and venetoclax to cytarabine and daunorubicin induction and cytarabine...

Sponsor: OHSU Knight Cancer InstituteEnrolling: 1021 location
RECRUITINGPhase 2NCT05031897

Two Step Haplo With Radiation Conditioning

This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell...

Sponsor: Thomas Jefferson UniversityEnrolling: 631 location
RECRUITINGPhase 1NCT06372717

A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS

This is an open-label, Phase 1 study to determine the safety, tolerability, and efficacy of APL-4098 alone, and in combination with azacitidine, and in combination with...

Sponsor: Apollo Therapeutics LtdEnrolling: 1009 locations
RECRUITINGPhase 1NCT05287568

CC-486 and Venetoclax for Acute Myeloid Leukemia

This is an open label, dose escalation Phase I single institution pilot study for relapsed and refractory AML patients using CC-486 (oral azacitidine) with venetoclax. At the...

Sponsor: University of Colorado, DenverEnrolling: 352 locations
RECRUITINGPhase 1 / Phase 2NCT05366218

Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia

The objective of the trial is to evaluate the safety, clinical toxicity and in vivo immunological effects of MOR00208 in pediatric patients with acute lymphoblastic leukemia who...

Sponsor: University Hospital TuebingenEnrolling: 2011 locations
RECRUITINGPhase 2NCT07188610

PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma

\*\*Translation:\*\* This clinical trial is designed as a single-arm, open-label, multicenter study. After signing the informed consent form, eligible subjects will undergo a...

Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.Enrolling: 10015 locations
RECRUITINGPhase 1NCT05043571

CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia

The objective of this study is to assess the safety and efficacy of anti-CD7 CAR T-cells in patients with refractory or relapsed T-lineage acute lymphoblastic leukemia (T-ALL).

Sponsor: National University Hospital, SingaporeEnrolling: 201 location
RECRUITINGNCT06409767

Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive...

Patients with hematologic malignancies requiring intensive chemotherapy are at risk for life-threatening complications. Organ failure may appear rapidly and delay in initiating...

Sponsor: University Hospital, AngersEnrolling: 222410 locations
RECRUITINGNCT04645199

National Longitudinal Cohort of Hematological Diseases

Background Hematological diseases are disorders of the blood and hematopoietic organs. The current hematological cohorts are mostly based on single-center or multi-center cases,...

Sponsor: Institute of Hematology & Blood Diseases Hospital, ChinaEnrolling: 23001 location
RECRUITINGPhase 2NCT06698003

A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1

The purpose of this study is to find out whether the study drug mogamulizumab is effective in preventing the development of adult T-cell leukemia/lymphoma (ATL) in people who are...

Sponsor: Memorial Sloan Kettering Cancer CenterEnrolling: 1347 locations
RECRUITINGPhase 3NCT04269902

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia...

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk...

Sponsor: National Cancer Institute (NCI)Enrolling: 24720 locations
RECRUITINGPhase 1NCT06737523

Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML

To investigate the safety and efficacy of the CVA regimen, composed of Chiglitazar Sodium in combination with Venetoclax and Azacitidine, in the treatment of patients with...

Sponsor: The First Affiliated Hospital of Xiamen UniversityEnrolling: 301 location
RECRUITINGPhase 1NCT06712810

Q702 for the Treatment of Patients With Hematologic Malignancies

This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called...

Sponsor: Mayo ClinicEnrolling: 462 locations
RECRUITINGPhase 2NCT03999723

Combining Active and Passive DNA Hypomethylation

This is a multicentre, randomized, parallel-group, placebo-controlled, double-blind phase 2 study of the efficacy and safety of oral vitamin C supplement in combination with...

Sponsor: Kirsten GrønbækEnrolling: 19610 locations
RECRUITINGPhase 2NCT04888741

Methods of T Cell Depletion Trial (MoTD)

A multi-centre phase II trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin vs. Calcineurin inhibitor or Sirolimus-based...

Sponsor: University of BirminghamEnrolling: 40017 locations
RECRUITINGPhase 1NCT07040982

Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute...

This phase I trial tests the safety, side effects and best dose of asciminib as maintenance treatment for adults with Philadelphia chromosome positive acute lymphoblastic leukemia...

Sponsor: City of Hope Medical CenterEnrolling: 301 location
RECRUITINGNCT07268846

Use of Preoperative Postbiotic Supplementation in Colorectal Cancer Surgery

The treatment of colorectal cancer, in the absence of metastases, is primarily based on surgical removal. Colorectal surgery, which involves resecting part of the intestine and...

Sponsor: AC Camargo Cancer CenterEnrolling: 1641 location
RECRUITINGPhase 1 / Phase 2NCT05959694

A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic...

This is a phase Ib/II clinical trial to evaluate the safety and efficacy of TQB3909 tablets in patients with recurrent or refractory CLL/SLL.

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Enrolling: 10720 locations
RECRUITINGNCT04115241

Activity Levels in Bone Marrow Transplant Patients

Participants in this study will be receiving a bone marrow transplant. This study is designed to evaluate correlations between activity levels and length of stay, quality of life,...

Sponsor: Michael TomassonEnrolling: 2001 location
RECRUITINGPhase 1NCT04815356

Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and...

Background: CAR (Chimeric Antigen Receptor) T cell therapy is a type of cancer treatment in which a person s T cells (a type of immune cell) are changed in a laboratory to...

Sponsor: National Cancer Institute (NCI)Enrolling: 271 location
RECRUITINGPhase 2NCT06672146

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A...

This phase II MyeloMATCH treatment trial studies how well ASTX727 and venetoclax plus enasidenib works compared to ASTX727 and venetoclax alone for the treatment of older patients...

Sponsor: National Cancer Institute (NCI)Enrolling: 9320 locations
RECRUITINGNCT06792994

A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients...

This observational trial is designed to investigate long-term survival with regard to the primary endpoint overall survival (OS) after start of first-line treatment.

Sponsor: German CLL Study GroupEnrolling: 20002 locations
RECRUITINGPhase 1 / Phase 2NCT03938987

Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory...

Autologous, unselected CD3+ lymphocytes collected from apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a...

Sponsor: University of AlbertaEnrolling: 636 locations
RECRUITINGNCT07362225

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With...

The MPN PROGRESSion Registry is a multi-year, observational research study designed to improve understanding of myeloproliferative neoplasms (MPNs)-a group of rare, chronic blood...

Sponsor: MPN Research FoundationEnrolling: 50002 locations
RECRUITINGNCT07627568

Analysis of Biomarkers in Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Treated With...

The white blood cells of patients with acute myeloid leukemia that have undergone allogeneic stem cell transplantation will be investigated. These are patient where the leukemia...

Sponsor: University of FreiburgEnrolling: 201 location
RECRUITINGPhase 1NCT07066397

A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL

This is a Phase 1 study to evaluate FIT-CD19-CAR-T (ARM011) safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.

Sponsor: TriArm Therapeutics (Taiwan) LimitedEnrolling: 121 location
RECRUITINGNCT06301425

MRD Response-adapted Allo-HSCT for Adverse-risk AML

This TROPHY-AML01 regimen aims to identify the effectiveness and safety of MRD response-adapted allo-HSCT for adverse-risk acute myeloid leukemia in an open-label, randomized,...

Sponsor: Peking University People's HospitalEnrolling: 1781 location
RECRUITINGPhase 2NCT05870917

A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia

This is a single-arm, open-label study to evaluate the efficacy and safety of VRD-based Regimen (Bortezomib, Lenalidomide and Dexamethasone) combined with CART-ASCT-CART2 in...

Sponsor: Institute of Hematology & Blood Diseases Hospital, ChinaEnrolling: 201 location
RECRUITINGNCT06600568

Novel Therapeutic Approach for Human T-cell Malignancies

This multicenter translational study, with prospective and retrospective samples, aims to identify new strategies to selectively eliminate neoplastic T cells by modulating...

Sponsor: Istituto Oncologico Veneto IRCCSEnrolling: 1202 locations
RECRUITINGPhase 1NCT06173518

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute...

This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19...

Sponsor: Autolus LimitedEnrolling: 308 locations

Showing 50 of 109 trials.Search all Acute Myeloid Leukemia trials

Frequently Asked Questions

There are currently 109 clinical trials for Acute Myeloid Leukemia, with 109 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Acute Myeloid Leukemia, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 4 Phase 3 trials for Acute Myeloid Leukemia, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.